Page 12 - Read Online

Page 6 of 6 Best et al. Hepatoma Res 2021;7:32 https://dx.doi.org/10.20517/2394-5079.2021.52

2012;55:483-90. DOI PubMed PMC
12. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and
hepatocellular carcinomas. Hum Pathol 2006;37:1435-41. DOI PubMed
13. Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular
carcinoma. N Engl J Med 1984;310:1427-31. DOI PubMed
14. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-
9. DOI PubMed
15. Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model
based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014;23:144-53. DOI PubMed
16. Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma
and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14:875-86.e6. DOI PubMed
17. Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with
nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728-35.e4. DOI PubMed
18. Venerito M, Pech M, Canbay A, et al. NEMESIS: noninferiority, individual-patient metaanalysis of selective internal radiation therapy
with (90)y resin microspheres versus sorafenib in advanced hepatocellular carcinoma. J Nucl Med 2020;61:1736-42. DOI PubMed
19. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med 2008;359:378-90. DOI PubMed
20. Bruix J, Qin S, Merle P, et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. DOI
PubMed
21. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI PubMed
22. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J
Med 2018;379:54-63. DOI PubMed PMC
23. Zhu AX, Kang YK, Yen CJ, et al; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced
hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled,
phase 3 trial. Lancet Oncol 2019;20:282-96. DOI PubMed
24. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
N Engl J Med 2020;382:1894-905. DOI PubMed